Pembrolizumab in combination with FOLFIRINOX for treatment of advanced pancreatic adenocarcinoma with MSI-H

Abstract

Pancreatic cancer is one of the four most common causes of cancer-related death in the United States. Our patient had metastatic pancreatic cancer with a high tumour burden. He was trialled on an unconventional treatment of combination immunotherapy and chemotherapy. It resulted in decreased cancer burden and decreased FDG activity on a PET scan. Further studies are needed for standard pancreatic cancer treatment.

Keywords

• msi-h
• pembrolizumab
• pancreatic adenocarcinoma